ARGX vs KMDA vs MCK Stock Comparison

Argenx Se, Kamada and Mckesson Prices as of Oct 27, 2026 Peers: Industry group
ARGX Argenx Se
$882.48 -8.0% 1M +6.3% 1Y
Market cap
$54.61B
P/E
28.8x
Revenue (TTM)
$5.82B
Div. yield
–
Biotechnology Healthcare
3 wins
KMDA Kamada Ltd
$8.05 -7.7% 1M +14.5% 1Y
Market cap
$464.37M
P/E
21.0x
Revenue (TTM)
$191.85M
Div. yield
5.22%
Biotechnology Healthcare
4 wins
MCK Mckesson Corp
$967.03 +11.6% 1M +19.2% 1Y
Market cap
$112.75B
P/E
25.0x
Revenue (TTM)
$410.98B
Div. yield
0.35%
Drug Distribution Healthcare
5 wins

Head to Head

12 decided of 12

Mckesson leads on 5 of the 12 questions below (Mckesson 5, Kamada 4, Argenx Se 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionARGXKMDAMCKLeader
Larger companyMarket capitalisation $54.61B $464.37M $112.75B MCK
Cheaper on earningsLower P/E, profitable companies only 28.8x 21.0x 25.0x KMDA
Cheaper on forward earningsLower price / next fiscal year consensus EPS 28.8x 16.1x 20.5x KMDA
Faster revenue growthRevenue growth, trailing twelve months +61.5% +13.2% +8.8% ARGX
More profitableNet margin, trailing twelve months 32.3% 11.5% 1.1% ARGX
Better return on capitalReturn on invested capital — 10.2% 107.9% MCK
Less leveragedLower net debt / EBITDA — -1.5x 0.6x KMDA
Higher dividend yieldTrailing dividend yield — 5.22% 0.35% KMDA
Better 1-year returnPrice return, last 12 months +6.3% +14.5% +19.2% MCK
Better 5-year returnAnnualised price return, 5 years +25.8%/yr +7.0%/yr +36.4%/yr MCK
Less volatileAnnualised volatility, 1 year 36.9% 34.7% 30.7% MCK
Higher overall scoreMean of the five percentile scores vs peers 92/100 84/100 57/100 ARGX

Percentile Scorecard

ARGXKMDAMCK

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisARGXKMDAMCK
Valuation 84 #99 of 625 97 #22 of 625 50 #13 of 25
Growth 94 #35 of 602 71 #177 of 602 65 #9 of 24
Profitability 98 #11 of 551 88 #70 of 551 61 #10 of 24
Financial Health – 74 #169 of 656 52 #13 of 26
Shareholder Returns – 90 #38 of 365 57 #7 of 15
Overall 92 84 57
  • ARGX ranked among 672 companies in Pharmaceuticals and Biotechnology
  • KMDA ranked among 672 companies in Pharmaceuticals and Biotechnology
  • MCK ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodARGXKMDAMCKSPY
1 month -8.0%-7.7%+11.6% -0.2%
3 months +1.2%+14.0%+8.7% +3.9%
6 months +13.9%-1.2%+15.8% +8.2%
Year to date +4.9%+14.0%+17.9% +12.9%
1 year +6.3%+14.5%+19.2% +12.3%
3 years +91.9%+94.4%+115.8% +87.4%
3 years, per year +24.3%+24.8%+29.3% +23.3%
5 years +214.2%+40.2%+371.7% +67.9%
5 years, per year +25.8%+7.0%+36.4% +10.9%
10 years —+34.2%+502.5% +261.1%
10 years, per year —+3.0%+19.7% +13.7%

Risk

MeasureARGXKMDAMCKSPY
Volatility, 1Y 36.9%34.7%30.7% 12.7%
Downside volatility, 1Y 34.6%33.2%27.4% 12.7%
Beta vs S&P 500, 1Y 0.391.01-0.27 1.00
Return / volatility, 1Y 0.170.420.62 0.97
Max drawdown, 5Y -38.2%-44.4%-27.2% -25.4%
From 52-week high -16.7%-13.5%-6.1% -1.2%
52-week high $1,058.90$9.31$1,030.18 $779.14
52-week low $663.93$6.62$725.17 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleARGXKMDAMCK
P/E now vs peer median 28.8xmedian 17.2x 21.0xmedian 17.2x 25.0xmedian 23.9x
P/S now vs peer median 9.4xmedian 9.0x 2.4xmedian 9.0x 0.3xmedian 0.3x
EV/EBITDA now vs peer median —median 16.3x 9.3xmedian 16.3x 16.2xmedian 13.4x
P/FCF now vs peer median —median 18.7x 17.6xmedian 18.7x 17.6xmedian 15.5x
P/B now vs peer median —median 2.2x 1.7xmedian 2.2x -26.6xmedian 2.5x
PEG now vs peer median 0.27median 0.33 0.30median 0.33 2.09median 1.34

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsARGXKMDAMCK
Revenue $5.82B $191.85M $410.98B
Gross profit $5.24B $78.31M $14.96B
Operating income $1.74B $27.83M $6.50B
Net income $1.88B $22.25M $5.30B
Free cash flow – $26.32M $6.42B
R&D $1.80B $9.91M –
EPS (diluted) $28.43 $0.38 $38.52
Cash & equivalents – $29.47M $5.16B
Total debt – $74.86M $9.73B
Shares (diluted) 66.03M 58.35M 119.20M
Enterprise value $54.61B $173.43M $99.21B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricARGXKMDAMCK
P/E 28.8x 21.0x 25.0x
P/FCF – 17.6x 17.6x
P/Operating cash flow – 13.0x 16.5x
P/S 9.4x 2.4x 0.3x
P/B – 1.7x -26.6x
P/Tangible book – 1.7x -13.7x
EV/EBITDA – 9.3x 16.2x
EV/EBIT 31.4x 14.4x 18.1x
EV/Revenue 9.4x 2.1x 0.3x
EV/FCF – 15.2x 18.3x
EV/Operating cash flow – 11.2x 17.1x
PEG (3Y EPS CAGR) 0.27 0.30 2.09

Growth

14 metrics
MetricARGXKMDAMCK
Revenue growth (1Y) 61.5% 13.2% 8.8%
Revenue CAGR (3Y) 80.5% 9.6% 13.1%
Gross profit growth (1Y) 62.2% 5.9% 11.2%
Gross profit CAGR (3Y) 80.0% 12.9% 6.6%
Operating income growth (1Y) 120.6% 10.3% 46.6%
Operating income CAGR (3Y) 85.1% 43.1% 13.5%
Net income growth (1Y) 22.5% 17.0% 58.1%
Net income CAGR (3Y) 115.5% 258.5% 10.7%
EPS growth (1Y) 20.9% 14.5% 52.8%
EPS CAGR (3Y) 104.8% 70.4% 12.0%
Operating cash flow growth (1Y) – -10.9% 4.7%
Operating cash flow CAGR (3Y) – 5.6% 10.7%
Free cash flow growth (1Y) – -16.7% 6.8%
Free cash flow CAGR (3Y) – 1.0% 11.3%

Profitability

14 metrics
MetricARGXKMDAMCK
Gross margin 90.0% 40.8% 3.6%
EBITDA margin – 22.5% 1.8%
Operating margin 29.9% 14.5% 1.6%
Pretax margin 32.6% 13.9% 1.6%
Net margin 32.3% 11.5% 1.1%
FCF margin – 13.7% 1.6%
Operating cash flow margin – 18.6% 1.7%
Return on equity – 8.4% –
Return on assets – 5.8% 6.2%
Return on invested capital – 10.2% 107.9%
Return on capital employed – 8.3% 43.4%
Asset turnover – 0.5x 4.8x
Cash conversion (OCF / net income) – 1.6x 1.3x
Stock comp / revenue – 1.1% –

Financial Health

11 metrics
MetricARGXKMDAMCK
Debt / assets – 1.6% 11.0%
Debt / equity – 0.0x -2.3x
Net debt / EBITDA – -1.5x 0.6x
Debt / FCF – 0.2x 1.5x
Liabilities / assets – 29.6% 104.8%
Equity / assets – 70.4% -4.8%
Interest coverage 10,120x 93.7x 23.6x
Current ratio – 4.1x 0.9x
Quick ratio – 2.3x 0.5x
Cash ratio – 1.4x 0.1x
Altman Z-score – 3.60 5.89

Shareholder Returns

7 metrics
MetricARGXKMDAMCK
Dividend yield – 5.2% 0.4%
Net buyback yield – 0.0% 5.9%
Shareholder yield – 5.2% 6.2%
Payout ratio (earnings) – 129.6% 7.4%
Payout ratio (FCF) – 109.6% 6.1%
Dividend growth (1Y) – – 11.3%
Dividend CAGR (3Y) – – 10.0%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusARGXKMDAMCK
Forward P/E 28.8xFY2026 16.1xFY2026 20.5xFY2026
EPS, next fiscal year $30.63FY2026 $0.50FY2026 $47.15FY2026
EPS growth, next FY +56.5%FY2026 +38.9%FY2026 +20.6%FY2026
EPS growth, the year after +26.9% +24.0% +11.0%
Revenue, next fiscal year $6.08BFY2026 $209.90MFY2026 $444.47BFY2026
Revenue growth, next FY +43.1%FY2026 +16.3%FY2026 +10.2%FY2026
Revenue growth, the year after +22.9% +13.6% +1.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersARGXKMDAMCK
Held by institutions 46.1% 8.6% 89.1%
Institutions holding 504 50 2,009
Change in shares held, QoQ -2.0% -3.1% -0.7%
Institutions buying 264 24 881
Institutions selling 160 18 791
Buyers to sellers 1.65 1.33 1.11

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ARGXKMDAMCK
ARGX 1.00 0.16 -0.04
KMDA 0.16 1.00 -0.01
MCK -0.04 -0.01 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ARGX, KMDA and MCK?

Mckesson (MCK) is the largest by market capitalisation: Argenx Se (ARGX) $54.61B, Kamada (KMDA) $464.37M, Mckesson (MCK) $112.75B.

Which stock is cheaper, ARGX, KMDA and MCK?

Kamada (KMDA) trades on the lowest price-to-earnings ratio (Argenx Se (ARGX) 28.8x, Kamada (KMDA) 21.0x, Mckesson (MCK) 25.0x). On next year's consensus earnings, Kamada (KMDA) is cheapest (Argenx Se (ARGX) 28.8x, Kamada (KMDA) 16.1x, Mckesson (MCK) 20.5x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Argenx Se (ARGX) grew revenue fastest over the trailing twelve months: Argenx Se (ARGX) +61.5%, Kamada (KMDA) +13.2%, Mckesson (MCK) +8.8%.

Which company is more profitable?

Argenx Se (ARGX) has the highest net margin (Argenx Se (ARGX) 32.3%, Kamada (KMDA) 11.5%, Mckesson (MCK) 1.1%). On return on invested capital, Mckesson (MCK) leads (Kamada (KMDA) 10.2%, Mckesson (MCK) 107.9%).

Which stock has performed better?

Over the past year Mckesson (MCK) returned the most: Argenx Se (ARGX) +6.3%, Kamada (KMDA) +14.5%, Mckesson (MCK) +19.2%. Over five years, Mckesson (MCK) compounded fastest (Argenx Se (ARGX) +25.8%/yr, Kamada (KMDA) +7.0%/yr, Mckesson (MCK) +36.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Kamada (KMDA) has the highest dividend yield: Kamada (KMDA) 5.22%, Mckesson (MCK) 0.35%. Argenx Se (ARGX) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Mckesson (MCK) has been the steadiest (Argenx Se (ARGX) 36.9%, Kamada (KMDA) 34.7%, Mckesson (MCK) 30.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ARGX, KMDA and MCK?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Mckesson (MCK) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.